290 results about "Lymph Cell" patented technology

Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.

Methods of expanding tumor infiltrating lymphocytes (TILs) using a tumor necrosis factor receptor superfamily (TNFRSF) agonist, such as a 4-1BB agonist, a CD27 agonist, a glucocorticoid-induced TNF receptor-related agonist, an OX40 agonist, a HVEM agonist, or a CD95 agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein. In addition, in some embodiments, therapeutic combinations of TILs and TNFRSF agonists useful in the treatment of diseases such as cancer, including compositions, uses, and dosing regimens thereof, are disclosed herein.

In some embodiments, methods of expanding tumor infiltrating lymphocytes using AKT pathway inhibitors and methods of using the expanded tumor infiltrating lymphocytes in the treatment of human diseases, including cancers, are disclosed.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The invention provides an aurone compound and medical application thereof, and relates to an aurone compound and application thereof in preparation of drugs for preventing and treating myelosuppression or blood system diseases. The aurone compound provided by the invention can significantly improve the myelosuppression state caused by rusotinib and radiotherapy, can recover the generation of erythrocytes after mouse irradiation and use of rusotinib, and has a significant effect on the recovery of leukocytes, especially neutrophils and lymphocytes, of the irradiated mouse. The invention provides a new potential drug for treatment of myelosuppression or blood system diseases.

The invention provides application of lactobacillus paracasei IOB413 and a metagen thereof in preparation of a medicine for improving radioactive hematopoietic injury, and relates to the field of microorganisms. The lactobacillus paracasei IOB413 is preserved in the China General Microbiological Culture Collection Center on June 29, 2018, and the preservation number of the lactobacillus paracasei IOB413 is CGMCC (China General Microbiological Culture Collection Center) No.16022. The lactobacillus paracasei IOB413 has the advantages that the lactobacillus paracasei IOB413 is preserved in the China General Microbiological Culture Collection Center; the lactobacillus paracasei IOB413 and the metaplasm thereof can improve the damage condition of immune organs, increase the number of lymphocytes, increase the number of red blood cells and blood platelets and recover the immune function and hematopoietic function of the organism, so that the radioactive hematopoietic damage is improved.

The invention relates to the field of biological medicines, in particular to a chimeric cytokine activated receptor for activating lymphocytes by using soluble immunosuppressive molecules and application of the chimeric cytokine activated receptor in tumor treatment. The chimeric cytokine activation receptor and a chimeric antigen receptor for recognizing tumor antigens are connected in parallel to form a co-expressed polycistron structure. Wherein the chimeric cytokine activation receptor comprises an scFv structural domain, a transmembrane structural domain and a cytokine chimeric activation structural domain which specifically recognize and bind soluble immunosuppressive molecules. The CAR-NK cell can specifically recognize soluble inhibitory factors in the tumor microenvironment and improve the in-vivo and in-vitro anti-tumor efficacy of the CAR-NK cell, and can be used for treating solid malignant tumors.

The present disclosure provides a PD1 targeted novel IL-2 VitoKine composition, featuring a high-affinity PD1 antibody domain and a bio-activable IL- 2 domain with optimally reduced potency. The PD1 Ab-IL2 VitoKine platform mitigates IL-2 therapy-related toxicities and synergizes the anti-tumor effects of PD1 and IL- 2 by: 1) efficiently targeting an inert IL-2 directly to tumor-infiltrating lymphocytes (TILs); 2) ensuring highly tumorspecific activation of the IL- 2 domain by TME- enriched proteases that co-localized with TILs; 3) allowing PD1 Ab and activated IL- 2 to act on intratumoral CD8+T cells in cis. The VitoKine demonstrates greatly enhanced concealment efficiency and has a lower intrinsic basal activity than what would typically be expected from the VitoKine platform incorporating a non-attenuated IL-2. This improvement permits a substantially higher dose tolerance, enabling safe administration at efficacious dose levels of the PD1 antibody, reversing T- cell anergy or exhaustion and further synergizing with IL-2 mediated anticancer immune response.

The invention discloses an effect of an Intestinia butyriproducens bacterium in anti-tumor immunotherapy, and finds that colonization of the Intestinia butyriproducens bacterium in intestinal tracts can inhibit growth of CT26 mouse subcutaneous transplanted tumors with poor response to the tumor immunotherapy, meanwhile, growth of human colorectal cancer cells is remarkably inhibited, and apoptosis of tumor cells is promoted for the first time. The application of the Intestinia butyriproducens bacterium in the anti-tumor immunotherapy has the advantages that the effect of the intestinia butyriproducens bacterium in the anti-tumor immunotherapy is achieved, and the application of the intestinia butyriproducens bacterium in the anti-tumor immunotherapy in the anti-tumor immunotherapy in the anti-tumor immunotherapy in the anti-tumor immunotherapy is achieved. Meanwhile, after colonization of the strain and combined administration of PD-1 monoclonal antibodies, the proportion of CD8 + T cells in mouse tumor infiltration lymphocytes is increased, the proportion of depleted PD-1 + CD8 + T cells is reduced, and the proportion of CD8 + T cells releasing functional cell factors interferon gamma and granzyme B is also increased, which shows that after colonization of the strain, the curative effect of tumor immunotherapy can be enhanced, and the tumor immunotherapy effect can be enhanced. The immunoregulation capability and the great clinical application value are realized.

The present disclosure relates to methods of making genetically engineered lymphocytes. In addition, methods of using genetically engineered lymphocytes in T cell therapy of cancer are also disclosed.

The present invention relates to assays, methods, and kits to assess traumatic brain injury (TBI) in a subject. The present invention also relates to ultrasensitive assays for GFAP, tau, CKBB, IL-1β, IL-2, IL-6, IL-10, IL-22, IP-10, TNFα, TSLP, NFL, and / or NFH.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The invention relates to the field of biological medicine, in particular to application of fermented lactobacillus mucus in preparation of immune antitumor drugs. A strain of fermented lactobacillus mucus capable of effectively treating tumors is screened and can activate the immune system of the strain, increase the proportion of CD8 + T lymphocytes in spleen tissues, increase the infiltration proportion of leukocytes in tumors and the proportion of CD4 + and CD8 + T lymphocytes in infiltrated immune cells, change the tumor microenvironment and improve the tumor immunity. Therefore, tumor cells are effectively killed, and the effect of tumor immunotherapy is achieved.

The invention discloses a gene-edited tumor infiltrating lymphocyte and a T cell receptor engineered T cell and application thereof in immunotherapy. According to the invention, NR4A1 and / or NR4A2 and / or NR4A3 genes are / is knocked out from tumor infiltrating lymphocytes or T cell receptor engineered T cells, so that the multiplication capacity and the anti-tumor capacity of the tumor infiltrating lymphocytes or T cell receptor engineered T cells are improved.

The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and / or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.

The invention discloses a trophoblast-free one-step culture method and application of tumor infiltrating lymphocytes, and particularly discloses a one-step amplification method of tumor infiltrating lymphocytes, which comprises the following steps: treating a tumor sample obtained from a subject into tumor segments; the tumor segments are cultured in a culture medium containing a CD3 agonist, a 4-1BB agonist and IL-2, so that an amplified tumor infiltration lymphocyte population is obtained, and the culture medium does not contain trophoblastic cells. Compared with the prior art, the method has the advantages that the required period for amplifying the tumor infiltrating lymphocytes is shorter, the cost is lower, the cell effect function is stronger, and the clinical application range of the tumor infiltrating lymphocyte therapy is widened.

The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.

The invention provides pathological tissue section dyeing equipment and method. The method comprises the following steps: dividing a to-be-dyed lymphatic tissue section into a plurality of dyeing partitions according to the structural characteristics of lymphocyte tissues in the to-be-dyed lymphatic tissue section; dyeing agents with different concentrations are applied to different dyeing partitions according to the reference light transmittance of the lymphocyte tissue to obtain color gradient vectors of the lymphocyte tissue slices, light absorption characteristics of the dyeing partitions are measured through a photometer, and dyeing characteristics are determined based on the light absorption characteristics and the color gradient vectors; obtaining a dyeing image after dyeing the lymph tissue section, extracting deep features of the dyeing partitions from the dyeing image, and determining a dyeing loss value when dyeing the dyeing partitions based on the deep features and the dyeing features; and based on the dyeing loss value, carrying out self-adaptive adjustment on the dyeing agent concentration of each dyeing zone. By adopting the scheme provided by the invention, optimal adjustment on the concentration of the coloring agent in the sample dyeing process can be realized based on the characteristic difference of the cell tissues at different parts.

The invention discloses a biomarker for predicting the prognosis condition of sepsis and application, and belongs to the technical field of biology. The biomarkers comprise a ratio of neutrophils to lymphocytes, a ratio of platelets to lymphocytes, a ratio of monocytes to lymphocytes, a ratio of leukocytes to lymphocytes, a system inflammatory response index and a peripheral inflammatory value. According to the method, the ratio of neutrophil to lymphocyte, the ratio of platelet to lymphocyte, the ratio of mononuclear cell to lymphocyte, the ratio of leukocyte to lymphocyte, a systemic inflammatory response index and a peripheral inflammatory value are utilized to carry out accurate prognosis risk stratification on the sepsis patient, and prognosis survival risk prediction is carried out on the sepsis patient; the accuracy and timeliness of prognosis evaluation of sepsis patients are remarkably improved, a reliable guidance basis is provided for clinical decision making, and the method has important clinical application value and popularization significance.

The invention discloses a lactobacillus fermentum strain as well as extracellular vesicles and application thereof. The lactobacillus fermentum strain is named as C283, is preserved in the General Microbiological Center of the China Committee for Culture Collection of Microorganisms, and has the microbial preservation number of CGMCC No.30338. The lactobacillus fermentum strain can be used for preparing the lactobacillus fermentum. Researches show that the strain has unique anti-inflammatory and anti-infection dual characteristics, and also has the characteristics of acid resistance, cholate resistance and the like; particularly, the C283 strain can generate extracellular vesicles with very strong immunologic adjuvant activity and immunological enhancement activity, and the C283 strain outer vesicles can directly activate chicken mucous membrane epithelium lymphocytes only through nasal dripping and eye dripping, so that mucous membrane immune response is remarkably enhanced; particularly, the strain exovesicle can be directly used as an efficient mucosal delivery carrier for inactivated viruses or antigens, nucleic acid vaccines or mRNA vaccines, and efficient mucosal immune system delivery of the inactivated vaccines or antigens can be achieved in a mucosal immune mode. The invention provides a new technical means for preparing novel oral vaccines and mucous membrane delivery vaccines.

The invention provides a method for constructing a malignant pleuroperitoneal fluid-derived gastric cancer cell organoid model. The method comprises malignant pleuroperitoneal fluid sample treatment, gastric cancer cell separation and gastric cancer cell organoid culture. Gastric cancer cells and lymphocytes are separated through layer-by-layer treatment of malignant pleuroperitoneal fluid samples, so that the purity of the gastric cancer cells in the gastric cancer cell organ model can be improved, the proportion of immune cells can be reduced, the authenticity and accuracy of the gastric cancer cell organ model can be enhanced, and the heterogeneity and individualized characteristics of gastric cancer patients can be reflected; therefore, the method has important value for clinical drug screening and precise treatment of gastric cancer patients.

The invention discloses a key effect and a targeted intervention strategy of YTHDF1 in regulation and control of a hepatocellular carcinoma immunosuppression microenvironment. In the tumor-associated fibroblasts, YTHDF1 enhances the translation efficiency of OTUD5 mRNA through an m6A dependency mechanism, an up-regulated deubiquitination enzyme OTUD5 is directly combined with a tryptophan metabolic rate-limiting enzyme IDO1, ubiquitination degradation of the tryptophan metabolic rate-limiting enzyme IDO1 is inhibited, tryptophan is further driven to catabolism to generate kynurenine, regulatory T cell differentiation is promoted, and an immunosuppression microenvironment is formed. Spatial transcriptomics shows that YTHDF1 + CAFs and Tregs are significantly co-localized in tumor tissues and have metabolic interaction. Based on artificial intelligence virtual screening, it is found that a natural compound hesperidin can be specifically combined with a YTH structural domain of YTHDF1, an OTUD5-IDO1 signal axis mediated by the natural compound hesperidin is blocked, and the KYN level is remarkably reduced. Animal experiments prove that the tumor inhibition rate of combined treatment of hesperidin and anti-PD-1 is increased by 40% or above compared with that of a single drug group, and synergistic interaction is achieved by inhibiting Tregs infiltration and enhancing the activity of cytotoxic T lymphocytes.

The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The invention relates to a compound. The compound comprises a polysaccharide conjugate, an anti-PD-L1 monoclonal antibody and a PKM2 inhibitor. The compound disclosed by the invention can be accumulated and retained in tumor tissues, so that dendritic cells are effectively stimulated to be mature, an inhibitory immune microenvironment is relieved, and a specific anti-tumor immune response is initiated. The expression of PKM2 can be effectively inhibited, so that glycolysis in tumor tissues is inhibited, and a more favorable environment is provided for infiltrating the tumor tissues with T lymphocytes. The compound disclosed by the invention is expected to enhance the treatment effect of RFA on advanced HCC patients by reprogramming iRFA-induced tumor immunosuppression, and has huge potential in the aspect of improving prognosis of the advanced HCC patients treated by the RFA.

The invention relates to the technical field of biology and medicine, in particular to a ULBP2 specific chimeric antigen receptor, a CAR-T cell and application of the ULBP2 specific chimeric antigen receptor. The ULBP2 specific chimeric antigen receptor comprises a ULBP2 antigen binding structural domain, a transmembrane structural domain and an intracellular signal transduction structural domain, wherein the ULBP2 antigen binding structural domain comprises an amino acid sequence as shown in SEQ ID NO: 1. After lymphocytes are transduced by the ULBP2 specific chimeric antigen receptor disclosed by the invention, the killing capability of the lymphocytes on tumor cells is remarkably enhanced, and particularly, the ULBP2 specific chimeric antigen receptor has a remarkable directional killing effect on tumor cells with high expression of ULBP2. The invention also relates to the application of the ULBP2 specific CAR-T cell and an anti-PD1 antibody in combined treatment of cancers.

The invention discloses an application of a pyrrosia lingua aqueous extract in preparation of a medicine for preventing and treating radioactive intestinal injury. Radioactive intestinal injury is a common complication of ionizing radiation, and has main pathological characteristics of intestinal mucosal barrier destruction, excessive release of inflammatory factors, increase of oxidative stress level and hematopoiesis and immune function inhibition. At present, no effective and safe prevention and treatment medicine is available. It is found for the first time that the pyrrosia lingua aqueous extract can inhibit expression (IL-6, TNF-alpha and IL-1beta) of inflammatory factors of radiation-induced MODE-K cells and relieve the oxidative stress level (malondialdehyde (MDA) is reduced, and the content of superoxide dismutase (SOD) and glutathione (GSH) is increased). In animal experiments, the pyrrosia lingua aqueous extract can reduce the levels of TNF-alpha and IL-1beta inflammatory factors in serum of irradiated mice and improve oxidative stress disorders such as MDA increase, SOD and GSH decrease and the like; the reduction of leukocytes and lymphocytes is relieved; the length of intestinal villus is promoted and recovered; the proportion of Ki67 positive cells in a crypt region is increased, so that the regeneration capacity of intestinal epithelial cells is enhanced. The pyrrosia lingua aqueous extract disclosed by the invention provides an experimental basis and an application prospect for developing a novel medicine for preventing and treating the radioactive intestinal injury.

The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma by administration of Compound (I), or a pharmaceutically acceptable salt thereof.

The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.